Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GCM2 CRISPR/Cas9 KO Plasmid (m): sc-430769
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GCM2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GCM2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GCM2 Antibody (C-5): sc-390603
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCM2 CRISPR/Cas9 KO Plasmid (m) | sc-430769 | 20 µg | $397.00 |
Overview
Gcm2 encodes the transcription factor GCM2, a member of the glial cells missing family that binds DNA to regulate lineage-specific gene expression programs. In mouse development, GCM2 is critical for parathyroid gland specification and maintenance, coordinating transcriptional networks that support calcium and phosphate homeostasis through regulation of parathyroid hormone–associated pathways. Disruption of Gcm2 perturbs differentiation and endocrine tissue identity, making it a useful node for studying transcriptional control of organogenesis. Altered GCM2 function is linked to parathyroid developmental defects and dysregulated mineral metabolism phenotypes, supporting its relevance in models of endocrine and metabolic disease mechanisms.
GCM2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Gcm2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Gcm2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Gcm2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GCM2 protein expression.
This CRISPR knockout system enables efficient generation of Gcm2-deficient cell models for investigation of GCM2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Gcm2 exon(s) critical for GCM2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Gcm2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GCM2 CRISPR/Cas9 KO Plasmid (m) and GCM2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Gcm2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GCM2 HDR Plasmid (m) and GCM2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Gcm2 homology arms to support homology-directed repair at defined Gcm2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.